TELO GENOMICS CORP - TDSGF STOCK NEWS

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has received approval for the IPON program, which provides up to CAD 80,000 in IP cost reimbursement plus strategic guidance. The company holds 23 patents (20 granted) covering its TeloView technology across Canada, US, and Europe. Recent patent applications for TeloViewSMM, their flagship product for smoldering multiple myeloma (SMM), would extend protection until 2043. The TeloViewSMM test, clinically validated with Mayo Clinic and Dana Farber Institute, is available as a CLIA laboratory developed test, offering non-invasive risk assessment for SMM patients with an estimated market of over 500,000 tests annually.

Telo Genomics has expanded its collaboration with Mayo Clinic to include participation in their Physician Experience Program SMART, utilizing the TeloViewSMM prognostic test for smoldering multiple myeloma patients. The amendment also covers patient samples for blind validation of TeloViewNDMM, a test for newly diagnosed multiple myeloma patients, as a final step toward adding it as a Laboratory Developed Test. The TeloViewNDMM test aims to identify patients who will relapse on first-line therapy within a year or confirm treatment stability. The collaboration, initiated in 2020, has already led to the successful validation of TeloViewSMM, with results published in the American Journal of Hematology.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has presented new performance data for its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the International Myeloma Society (IMS) 2024 annual meeting. The test outperformed the current 20-2-20 scoring model in identifying both high-risk and low-risk patients in a cohort of 160 SMM patients.

Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the NCCN Myeloma Committee, presented the results. The TeloViewSMM test addresses a critical unmet need in SMM patient management, stratifying patients between high-risk and low-risk progression to full-stage multiple myeloma. This non-invasive liquid biopsy test can be performed using a simple blood draw and used periodically.

The company estimates the total addressable market for TeloViewSMM could result in over 500,000 tests per year, based on recent demographic studies showing SMM prevalence in approximately 0.5% of the population over 40 years old.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) is evaluating its minimal residual disease (MRD) biomarker assay in multiple myeloma patients as part of the TELO-DMRD clinical validation study. The company is collaborating with McGill University and using Adaptive Biotechnologies' clonoSEQ assay to validate the sensitivity of its MRD assay. The study aims to develop two prognostic tests for monitoring myeloma MRD:

1. Identify and quantify MRD cells in blood post marrow transplantation
2. Profile isolated MRD cells using Telo's proprietary TeloView technology

These liquid biopsy-based tests are designed to assess disease aggressiveness in individual MRD cells. The initial evaluation includes up to ten patients, with potential for expansion based on results.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has received CLIA certification from the US Centers for Medicare & Medicaid Services. This important milestone allows Telo to offer its clinical laboratory services within the USA and develop and validate its TeloView prognostic products for distribution in the USA and other international jurisdictions recognizing International CLIA accreditation.

The CLIA certification, combined with the recently achieved CAP accreditation, enables Telo to demonstrate the viability of its TeloView prognostic products to potential US partners. This achievement is expected to advance Telo's platform of prognostic tests across oncology and empower ongoing partnership development efforts with key industry players, particularly in smoldering and minimal residual disease (MRD) in multiple myeloma.

Telo Genomics Corp. announced that its TeloViewSMM test for smoldering multiple myeloma (SMM) has been accepted as a Laboratory Developed Test (LDT) by the College of American Pathologists (CAP). This test, validated with Mayo Clinic and Dana Farber Cancer Institute, identifies high-risk SMM patients with 83% sensitivity and 76% specificity, helping to manage treatment intervention. The test will be added to Telo's CAP-approved menu, allowing it to be offered to US hospitals and cancer centers. CAP's approval was granted without an onsite assessment, reflecting Telo's prior demonstrated excellence.

Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3D0A) presented its AI-driven TeloView myeloma diagnostic tests at the ASCO 2024 meeting. The company introduced CellSelect-Pro™, a machine learning tool enhancing sample processing accuracy and efficiency, yielding a 20-25% cost saving over manual methods. CellSelect-Pro achieved over 90% accuracy and over 80% precision, validated with 20 patient samples. This tool integrates with Telo's TeloViewSMM for smoldering multiple myeloma (SMM) and is part of their MRD clinical trial at McGill University. Recently, Telo published a significant SMM study in the American Journal of Hematology, further validating their technology. President Sherif Louis highlighted the interest and positive reception of CellSelect-Pro at ASCO, marking a step toward commercialization and industry partnerships.

Telo Genomics announced the publication of results from its smoldering multiple myeloma (SMM) study in the American Journal of Hematology. The study, involving 168 patients, demonstrated superior performance of the TeloViewSMM test with an 85% positive predictive value and a 73% negative predictive value. The test, developed in collaboration with Mayo Clinic, distinguishes high-risk SMM patients from stable ones, aiding in treatment decisions. This non-invasive test addresses a critical need in SMM management and has potential applications in other cancers.

Telo Genomics (TSXV: TELO, OTCQB: TDSGF), a biotech firm specializing in telomere technology for oncology diagnostics, has entered into a collaboration with Emery Pharma, a CRO specializing in biologic drug development.

This partnership aims to merge their innovative technologies to provide enhanced bioanalytical solutions for clinical research. The TeloView platform from Telo offers high-sensitivity genomic instability insights, while Emery Pharma delivers comprehensive biologic characterization services.

The Memorandum of Understanding (MOU) sets the stage for collaborative efforts to address unmet needs in pharma and diagnostics. Executives from both companies expressed optimism about the potential synergies and future developments.